Does SOTORASIB Cause Therapy partial responder? 49 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 49 reports of Therapy partial responder have been filed in association with SOTORASIB (LUMAKRAS). This represents 1.7% of all adverse event reports for SOTORASIB.
49
Reports of Therapy partial responder with SOTORASIB
1.7%
of all SOTORASIB reports
13
Deaths
2
Hospitalizations
How Dangerous Is Therapy partial responder From SOTORASIB?
Of the 49 reports, 13 (26.5%) resulted in death, 2 (4.1%) required hospitalization, and 1 (2.0%) were considered life-threatening.
Is Therapy partial responder Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SOTORASIB. However, 49 reports have been filed with the FAERS database.
What Other Side Effects Does SOTORASIB Cause?
Non-small cell lung cancer (483)
Death (319)
Disease progression (314)
Diarrhoea (284)
Off label use (193)
Nausea (98)
Non-small cell lung cancer metastatic (93)
Hepatotoxicity (91)
Fatigue (87)
Hepatic function abnormal (80)
What Other Drugs Cause Therapy partial responder?
CYCLOPHOSPHAMIDE (1,397)
RITUXIMAB (1,219)
DEXAMETHASONE (1,199)
PREDNISONE (1,176)
PEMBROLIZUMAB (1,125)
CARBOPLATIN (1,096)
DOXORUBICIN (834)
METHOTREXATE (775)
VINCRISTINE (707)
ETOPOSIDE (670)
Which SOTORASIB Alternatives Have Lower Therapy partial responder Risk?
SOTORASIB vs SOTROVIMAB
SOTORASIB vs SOVALDI
SOTORASIB vs SOYBEAN OIL
SOTORASIB vs SPARSENTAN
SOTORASIB vs SPARTALIZUMAB